Pharmaceutical Intermediates Market worth USD 37,290.33 million by 2028 - Exclusive Research by The Insight Partners

The pharmaceutical intermediates market is expected to reach US$ 37,290.33 million in 2028 from US$ 27,356.70 million in 2020. The market is estimated to grow with a CAGR of 4.2% from 2021-2028.

The report highlights trends prevailing in the market, and drivers and hindrances pertaining to the market growth. Factors such as rising prevalence of chronic diseases and infectious diseases, and escalating investment by pharmaceutical companies in R&D activities fuel the growth of the market. However, the high cost of drug manufacturing is the major factor hindersing the market growth.

The pharmaceutical intermediates market has been analyzed on the basis of type, application, distribution channel, and region. The market based on region is segmented into North America, Europe, Asia Pacific, the Middle East and Africa, and South and Central America. The report emphasizes on parameters such as market trends, technological advancements, market dynamics, and leading company's competitive landscape analysis to offers insights and in-depth analysis of the pharmaceutical intermediates market. It also includes the analysis of COVID-19 pandemic across the market in all the key regions.

Get Sample PDF Copy of Pharmaceutical Intermediates Market at: https://www.theinsightpartners.com/sample/TIPRE00005559/?utm_source=OpenPR&utm_medium=10408

Market Insights
Rising Prevalence of Chronic Diseases and Infectious Diseases
Pharmaceutical intermediates are the building blocks of active pharmaceutical ingredients (APIs). These are raw materials that undergo molecular change or processing during bulk drug production. Thus, the requirement of pharmaceutical intermediates increases with the rise in demand for drugs to treat chronic diseases. As per the Centers for Disease Control and Prevention (CDC), 6 in 10 adults in the US suffer from at least one chronic disease such as cancer, heart disease, lung disease, stroke, neurological disease, diabetes, and kidney diseases. Moreover, 4 in 10 adults in the country have two or more chronic diseases. Additionally, according to the press release by the European Chronic Disease Alliance (ECDA), in 2014, 9 out of 10 people in Europe die due to chronic diseases. Thus, 70-80% of the total healthcare costs are spent on the management of chronic diseases.

The surging prevalence of infectious diseases, especially in Southeast Asia, is also likely to propel the demand for APIs in the coming years, eventually driving the growth of the pharmaceutical intermediate market. For instance, as per the Revised National Tuberculosis Control Programme Report, around 4.4 lakh patients died due to tuberculosis in India in 2018, that is 29% of the total 1.5 million deaths caused by the disease across the world. Thus, such high prevalence of chronic diseases and infectious diseases is bolstering the demand for drugs, eventually highlighting the need of pharmaceutical intermediates.

In 2020, the GMP segment accounted for the global pharmaceutical intermediate market's a largerst market share of the global pharmaceutical intermediate market. The market growth for this segment can be attributed to increase in adoption of good manufacturing practices (GMP) by pharmaceutical companies. Good Manufacturing Practice (GMP) are regulations by the US Food and Drug Administration that ensure that pharmaceutical products are consistently produced as per the quality standards. These regulations are designed to reduce the risks involved in the production of pharmaceuticals that cannot be eliminated through testing the finished product.

COVID-19 first began in Wuhan (China) during December 2019 and since then it has spread at a fast pace across the globe. The US, India, Brazil, Russia, France, the UK, Turkey, Italy, and Spain are some of the worst affected countries in terms confirmed cases and reported deaths. The COVID-19 has been affecting economies and industries in various countries due to lockdowns, travel bans, and business shutdowns.

Speak to Analyst for more details:
https://www.theinsightpartners.com/speak-to-analyst/TIPRE00005559/?utm_source=OpenPR&utm_medium=10408

Pharmaceutical Intermediates Market: Competitive Landscape and Key Developments
Pfizer Inc., .; Sanofi, ; BASF SE, ; Lianhe Chemical Technology Co., Ltd, ; Dishman Carbogen Amcis Ltd, ; Codexis, ; Midas Pharma GmbH, ; chiracon GmbH, ; Dextra Laboratories Limited, ; and Vertellus Holdings LLC are among the leading companies operating in the pharmaceutical intermediate market.

The companies are adopting inorganic and organic growth strategies to expand their global footprints and product portfolio to meet the rising demands for the pharmaceutical intermediate. For instance, in January 2021, Pritzker Private Capital, a leader in family direct investing, acquired the Vertellus group of companies, a specialty chemicals manufacturer. Headquartered in Indianapolis, Ind., Vertellus is a leading provider of specialty chemicals for the healthcare, personal care, food & agriculture, coatings, and transportation markets.

Order a Copy of Pharmaceutical Intermediates Market Shares, Strategies and Forecasts 2021-2028 Research Report at: https://www.theinsightpartners.com/buy/TIPRE00005559/?utm_source=OpenPR&utm_medium=10408

Contact Us:
If you have any queries about this report or if you would like further information, please contact us:
Contact Person: Sameer Joshi
E-mail: sales@theinsightpartners.com
Phone: +1-646-491-9876

About US
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defence, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Food and Beverages, Consumers and Goods, Chemicals and Materials.

This release was published on openPR.